Thrive Launches With $110M Series A Financing To Integrate Earlier Detection Of Multiple Cancer Types Into Routine Medical Care
Thrive Launches with $110 Million Series A Financing to Integrate Earlier Detection of Multiple Cancer Types into Routine Medical Care
Company Advancing CancerSEEK, A DNA- and Protein-based Liquid Biopsy Test Developed by The Vogelstein Lab at Johns Hopkins University
10,000 Person Prospective Trial Fully Enrolled with Geisinger; Financing Will Support Expanded Clinical Development to Enable Regulatory Approvals and Broad Reimbursement Access
Company Will Integrate Real-World Data and Machine Learning to Enable a Comprehensive Care Solution for Primary Care Physicians
Third Rock Ventures Led Financing Together with Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, Invus, Exact Sciences ...